AU2009220925A1 - Methods, dosage forms, and kits for administering ziprasidone without food - Google Patents

Methods, dosage forms, and kits for administering ziprasidone without food Download PDF

Info

Publication number
AU2009220925A1
AU2009220925A1 AU2009220925A AU2009220925A AU2009220925A1 AU 2009220925 A1 AU2009220925 A1 AU 2009220925A1 AU 2009220925 A AU2009220925 A AU 2009220925A AU 2009220925 A AU2009220925 A AU 2009220925A AU 2009220925 A1 AU2009220925 A1 AU 2009220925A1
Authority
AU
Australia
Prior art keywords
ziprasidone
dosage form
human
solid oral
oral dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009220925A
Other languages
English (en)
Inventor
William Caldwell Brett
Christopher Donovan Craig
William John Curatolo
Dwayne Thomas Friesen
Scott Max Herbig
Timothy Lukas
David Keith Lyon
Jaymin Chandrakant Shah
Sheri L. Shamblin
Avinash Govind Thombre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Publication of AU2009220925A1 publication Critical patent/AU2009220925A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2009220925A 2008-03-07 2009-03-04 Methods, dosage forms, and kits for administering ziprasidone without food Abandoned AU2009220925A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3494708P 2008-03-07 2008-03-07
US61/034,947 2008-03-07
PCT/IB2009/000442 WO2009109844A1 (en) 2008-03-07 2009-03-04 Methods, dosage forms, and kits for administering ziprasidone without food

Publications (1)

Publication Number Publication Date
AU2009220925A1 true AU2009220925A1 (en) 2009-09-11

Family

ID=40720011

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009220925A Abandoned AU2009220925A1 (en) 2008-03-07 2009-03-04 Methods, dosage forms, and kits for administering ziprasidone without food

Country Status (15)

Country Link
US (1) US20110002989A1 (OSRAM)
EP (1) EP2280711A1 (OSRAM)
JP (1) JP2009215293A (OSRAM)
KR (1) KR20100131477A (OSRAM)
CN (1) CN102014910A (OSRAM)
AR (1) AR070964A1 (OSRAM)
AU (1) AU2009220925A1 (OSRAM)
BR (1) BRPI0909818A2 (OSRAM)
CA (1) CA2719115A1 (OSRAM)
IL (1) IL207792A0 (OSRAM)
MX (1) MX2010009844A (OSRAM)
RU (1) RU2010135831A (OSRAM)
TW (1) TW200950783A (OSRAM)
WO (1) WO2009109844A1 (OSRAM)
ZA (1) ZA201005905B (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010082855A1 (en) * 2009-01-15 2010-07-22 Zaklady Farmaceutyczne Polpharma Sa Pharmaceutical compositions comprising ziprasidone free base or ziprasidone hydrochloride and the method for their preparation
US9510148B2 (en) * 2009-03-03 2016-11-29 Mobilitie, Llc System and method for wireless communication to permit audience participation
CN105492007A (zh) * 2013-05-03 2016-04-13 欣达克斯制药公司 癌症治疗方法
JP6153667B2 (ja) 2013-07-30 2017-06-28 ギリアード コネチカット， インコーポレイテッド Ｓｋｙ阻害剤の製剤
NZ715776A (en) 2013-07-30 2017-04-28 Gilead Connecticut Inc Polymorph of syk inhibitors
JP6505705B2 (ja) * 2013-12-05 2019-04-24 アルライズ バイオシステムズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 経口投与用製剤の製造方法
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
US10474345B2 (en) * 2014-04-04 2019-11-12 Shawn SHEY User interfaces and methods for displaying content
BR112017005283A2 (pt) * 2014-09-19 2017-12-12 Procter & Gamble processo para produção de um núcleo com um revestimento ativo
JP6796083B2 (ja) 2015-06-09 2020-12-02 カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップＣａｐｓｕｇｅｌ Ｂｅｌｇｉｕｍ ＮＶ カプセル中の薬剤の噴霧乾燥ディスパーションからの迅速な溶解を達成するための製剤
WO2016198113A1 (en) 2015-06-11 2016-12-15 Alrise Biosystems Gmbh Process for the preparation of drug loaded microparticles
CN107714669A (zh) * 2016-08-11 2018-02-23 广东东阳光药业有限公司 齐拉西酮缓释剂及其制备方法
US11384082B2 (en) 2017-08-25 2022-07-12 Kronos Bio, Inc. Hydrates of polymorphs of 6-(1H-indazol-6-YL)-N-(4-morpholinophenyl)-2,3-dihydroimidazo[1,2-A]pyrazin-8-amine bisemsylate as Syk inhibitors
CN113950479A (zh) 2019-02-22 2022-01-18 克洛诺斯生物股份有限公司 作为syk抑制剂的缩合吡嗪的固体形式

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002309172A1 (en) * 2001-06-22 2003-01-08 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
CN1874761A (zh) * 2003-09-02 2006-12-06 辉瑞产品公司 齐拉西酮的持续释放剂型
US7825106B2 (en) * 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
US20050163858A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Ziprasidone formulations
WO2005123086A2 (en) * 2004-06-11 2005-12-29 Dr. Reddy's Laboratories Ltd. Ziprasidone dosage form
KR20080024206A (ko) * 2005-06-20 2008-03-17 엘란 파마 인터내셔널 리미티드 아릴-헤테로시클릭 화합물을 함유하는 나노입자형 조절방출 조성물

Also Published As

Publication number Publication date
EP2280711A1 (en) 2011-02-09
TW200950783A (en) 2009-12-16
ZA201005905B (en) 2011-11-30
BRPI0909818A2 (pt) 2015-10-06
WO2009109844A1 (en) 2009-09-11
RU2010135831A (ru) 2012-04-20
US20110002989A1 (en) 2011-01-06
MX2010009844A (es) 2010-09-30
KR20100131477A (ko) 2010-12-15
AR070964A1 (es) 2010-05-19
CN102014910A (zh) 2011-04-13
JP2009215293A (ja) 2009-09-24
CA2719115A1 (en) 2009-09-11
IL207792A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
US20110002989A1 (en) Methods, dosage forms and kits for administering ziprasidone without food
US12447128B2 (en) Formulations of enzalutamide
JP2011516613A (ja) 好ましくはポサコナゾールおよびｈｐｍｃａｓを含む固体分散物中の経口用薬学的組成物
CN103976968A (zh) 包含二氢吡啶类钙通道拮抗剂的改进的药物组合物及其制备方法
JP2025134801A (ja) オラパリブの溶解度及び生体利用効率が改善された組成物
EP2540318A1 (en) Sustained-release solid preparation for oral use
US12502357B2 (en) Formulations of enzalutamide
HK1150392A (en) Methods, dosage forms, and kits for administering ziprasidone without food
HK40108713A (en) Formulations of enzalutamide
HK40116766A (en) Formulations of enzalutamide
HK40065232A (en) Formulations of enzalutamide
HK40037883A (en) Formulations of enzalutamide
HK40037883B (en) Formulations of enzalutamide

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application